Michael Method
Chief Medical Officer Bicycle Therapeutics plc
Dr. Michael Method is Chief Medical Officer at Bicycle Therapeutics, leading clinical development across the company’s oncology portfolio, including next-generation Bicycle® Radioconjugates. With more than three decades of experience in oncology drug development, he has held senior leadership positions at Karyopharm Therapeutics, ImmunoGen and Eli Lilly, overseeing programmes from first-in-human studies through to registration and commercialization. A former academic gynecologic oncologist and Director of Gynecologic Oncology at Indiana University School of Medicine, Michael combines deep clinical expertise with extensive experience in translational medicine, regulatory strategy and global clinical development of innovative cancer therapies.
Seminars
- Assessing the therapeutic potential of Lead-212 and the clinical rationale supporting its continued development
- Exploring the logistical and supply challenges associated with short half-life isotopes and how developers can successfully navigate them
- Understanding the balance between operational complexity and potential clinical advantages when selecting radionuclides
